ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 24 filers reported holding ALPINE IMMUNE SCIENCES INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $508,000 | -37.6% | 70,611 | -26.1% | 0.01% | -26.3% |
| Q2 2022 | $814,000 | -37.7% | 95,611 | -34.3% | 0.02% | -24.0% |
| Q1 2022 | $1,306,000 | -35.3% | 145,611 | 0.0% | 0.02% | -32.4% |
| Q4 2021 | $2,017,000 | +23.1% | 145,611 | -5.2% | 0.04% | +19.4% |
| Q3 2021 | $1,639,000 | +18.6% | 153,611 | 0.0% | 0.03% | +24.0% |
| Q2 2021 | $1,382,000 | +464.1% | 153,611 | +329.7% | 0.02% | +733.3% |
| Q1 2019 | $245,000 | +85.6% | 35,750 | 0.0% | 0.00% | +50.0% |
| Q4 2018 | $132,000 | -46.1% | 35,750 | -7.7% | 0.00% | 0.0% |
| Q3 2018 | $245,000 | -16.4% | 38,750 | 0.0% | 0.00% | -33.3% |
| Q2 2018 | $293,000 | -5.5% | 38,750 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $310,000 | -28.6% | 38,750 | 0.0% | 0.00% | -40.0% |
| Q4 2017 | $434,000 | +99.1% | 38,750 | +106.7% | 0.01% | +150.0% |
| Q3 2017 | $218,000 | – | 18,750 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 3,056,420 | $22,006,000 | 19.85% |
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $48,300,000 | 17.51% |
| GREAT POINT PARTNERS LLC | 3,448,521 | $24,829,000 | 5.98% |
| Omega Fund Management, LLC | 2,029,580 | $14,613,000 | 5.35% |
| Paradigm Biocapital Advisors LP | 2,214,722 | $15,946,000 | 2.13% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $21,497,000 | 1.66% |
| COMMODORE CAPITAL LP | 1,325,000 | $9,540,000 | 1.53% |
| Octagon Capital Advisors LP | 1,225,000 | $8,820,000 | 1.52% |
| RA Capital Management | 4,356,632 | $31,368,000 | 0.67% |
| TCG Crossover Management, LLC | 254,569 | $1,833,000 | 0.55% |